FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid
(Reuters) – The U.S. Food and Drug Administration approved AstraZeneca Plc and Merck & Co Inc’s Lynparza as a treatment for a form of prostate cancer, the companies said in a joint statement on Wednesday.
The drug approval is for patients with a form of gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Reporting by Aakash Jagadeesh Babu in Bengaluru; editing by Uttaresh.V
Our Standards:The Thomson Reuters Trust Principles.